On 4 March 2005, Sareum announced that it was in discussions with a party that may or may not lead to an offer being made for the Company. The Company announces that these discussions have terminated.

The Sareum directors continue to work to develop the Company's structure-based drug discovery and services business and remain confident about its future prospects.

  • @Sareumplc Latest tweet

    RT @HybridanLLP: Good plain English article looking at the autoimmune opportunities for Tyk2 inhibitors. The @Sareumplc compounds which ar… via @Sareumplc
    View more